Teladoc Health (TDOC) Stock Forecast, Price Target & Predictions
TDOC Stock Forecast
Teladoc Health stock forecast is as follows: an average price target of $50.87 (represents a 473.51% upside from TDOC’s last price of $8.87) and a rating consensus of 'Hold', based on 21 wall street analysts offering a 1-year stock forecast.
TDOC Price Target
The average price target for Teladoc Health (TDOC) is $50.87 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $9.00. This represents a potential 473.51% upside from TDOC's last price of $8.87.
TDOC Analyst Ratings
According to 21 Wall Street analysts, Teladoc Health's rating consensus is 'Hold'. The analyst rating breakdown for TDOC stock is 0 'Strong Buy' (0.00%), 10 'Buy' (47.62%), 11 'Hold' (52.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Teladoc Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Daniel Grosslight | Citigroup | $11.00 | $8.86 | 24.15% | 24.01% |
| Oct 30, 2024 | Elizabeth Anderson | Evercore ISI | $9.00 | $8.86 | 1.58% | 1.47% |
| Aug 06, 2024 | Jessica Tassan | Piper Sandler | $10.00 | $7.60 | 31.58% | 12.74% |
| Jun 11, 2024 | Steve Valiquette | Barclays | $20.00 | $10.48 | 90.75% | 125.48% |
| May 31, 2024 | Glen Santangelo | Jefferies | $10.00 | $11.29 | -11.43% | 12.74% |
| May 20, 2024 | Glen Santangelo | Jefferies | $14.00 | $12.39 | 12.99% | 57.84% |
| Apr 05, 2024 | George Hill | Deutsche Bank | $18.00 | $14.64 | 22.91% | 102.93% |
| Apr 12, 2023 | Jeff Garro | Stephens | $25.00 | $25.86 | -3.33% | 181.85% |
| Dec 13, 2022 | - | Citigroup | $33.00 | $27.63 | 19.44% | 272.04% |
| Sep 28, 2022 | - | RBC Capital | $35.00 | $27.52 | 27.18% | 294.59% |
The latest Teladoc Health stock forecast, released on Oct 31, 2024 by Daniel Grosslight from Citigroup, set a price target of $11.00, which represents a 24.15% increase from the stock price at the time of the forecast ($8.86), and a 24.01% increase from TDOC last price ($8.87).
Teladoc Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 7 |
| Avg Price Target | $10.00 | $10.00 | $13.14 |
| Last Closing Price | $8.87 | $8.87 | $8.87 |
| Upside/Downside | 12.74% | 12.74% | 48.14% |
In the current month, the average price target of Teladoc Health stock is $10.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 12.74% increase as opposed to Teladoc Health's last price of $8.87. This month's average price target is down 0.00% compared to last quarter, and down -23.90% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Barclays | Overweight | Overweight | Hold |
| Oct 31, 2024 | Citigroup | Neutral | Neutral | Hold |
| Oct 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 08, 2024 | RBC Capital | Buy | Buy | Hold |
| Oct 08, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 17, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 17, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 17, 2024 | Jefferies | Buy | Buy | Hold |
| Sep 17, 2024 | Jefferies | Hold | Hold | Hold |
| Aug 20, 2024 | Piper Sandler | Buy | Buy | Hold |
Teladoc Health's last stock rating was published by Barclays on Oct 31, 2024. The company gave TDOC a "Overweight" rating, the same as its previous rate.
Teladoc Health Financial Forecast
Teladoc Health Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $660.24M | $652.41M | $629.24M | $637.71M | $611.40M | $592.38M | $565.35M | $554.24M | $521.66M | $503.14M | $453.68M | $383.32M | $288.81M |
| Avg Forecast | $786.92M | $768.01M | $752.18M | $735.73M | $658.61M | $649.91M | $646.75M | $645.73M | $636.42M | $630.70M | $629.78M | $631.59M | $637.29M | $631.18M | $649.16M | $637.31M | $670.81M | $663.54M | $649.18M | $619.30M | $633.40M | $608.89M | $586.74M | $568.68M | $547.17M | $516.63M | $500.60M | $451.91M | $378.93M | $282.18M |
| High Forecast | $815.32M | $795.73M | $779.33M | $762.28M | $682.38M | $673.37M | $670.09M | $669.03M | $659.39M | $653.46M | $652.51M | $651.77M | $646.99M | $631.48M | $649.33M | $637.31M | $675.14M | $674.54M | $672.61M | $641.65M | $656.27M | $608.89M | $586.74M | $568.68M | $547.17M | $516.63M | $500.60M | $451.91M | $378.93M | $282.18M |
| Low Forecast | $753.49M | $735.39M | $720.22M | $704.47M | $630.63M | $622.30M | $619.27M | $618.29M | $609.38M | $603.90M | $603.02M | $601.10M | $615.89M | $630.87M | $649.00M | $637.31M | $667.50M | $656.16M | $621.60M | $592.99M | $606.49M | $608.89M | $586.74M | $568.68M | $547.17M | $516.63M | $500.60M | $451.91M | $378.93M | $282.18M |
| # Analysts | 6 | 6 | 6 | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 16 | 8 | 5 | 10 | 11 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.00% | 1.02% | 1.01% | 1.00% | 1.01% | 0.99% | 1.01% | 1.01% | 1.01% | 1.00% | 1.01% | 1.02% |
Teladoc Health's average Quarter revenue forecast for Dec 23 based on 11 analysts is $670.81M, with a low forecast of $667.50M, and a high forecast of $675.14M. TDOC's average Quarter revenue forecast represents a 1.60% increase compared to the company's last Quarter revenue of $660.24M (Sep 23).
Teladoc Health EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 16 | 8 | 5 | 10 | 11 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.39M | $31.15M | $24.51M | $3.83B | $-6.27M | $-1.97M | $-1.27M | $19.75M | $-1.54M | $-12.22M | $-20.27M | $-360.90M | $18.60M |
| Avg Forecast | $110.75M | $108.09M | $105.86M | $103.55M | $92.69M | $91.47M | $91.02M | $90.88M | $89.57M | $88.77M | $88.64M | $88.89M | $89.69M | $88.83M | $91.36M | $-375.52B | $94.41M | $93.39M | $91.37M | $-401.62B | $28.17M | $85.70M | $82.58M | $-429.54B | $77.01M | $72.71M | $70.46M | $-35.76M | $53.33M | $39.71M |
| High Forecast | $114.75M | $111.99M | $109.68M | $107.28M | $96.04M | $94.77M | $94.31M | $94.16M | $92.80M | $91.97M | $91.84M | $91.73M | $91.06M | $88.88M | $91.39M | $-300.41B | $95.02M | $94.94M | $94.66M | $-321.30B | $33.80M | $85.70M | $82.58M | $-343.63B | $77.01M | $72.71M | $70.46M | $-28.61M | $53.33M | $39.71M |
| Low Forecast | $106.05M | $103.50M | $101.37M | $99.15M | $88.76M | $87.58M | $87.16M | $87.02M | $85.77M | $84.99M | $84.87M | $84.60M | $86.68M | $88.79M | $91.34M | $-450.62B | $93.94M | $92.35M | $87.49M | $-481.94B | $22.53M | $85.70M | $82.58M | $-515.45B | $77.01M | $72.71M | $70.46M | $-42.91M | $53.33M | $39.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.34% | -0.00% | 135.96% | -0.07% | -0.02% | 0.00% | 0.26% | -0.02% | -0.17% | 0.57% | -6.77% | 0.47% |
11 analysts predict TDOC's average Quarter EBITDA for Dec 23 to be $94.41M, with a high of $95.02M and a low of $93.94M. This is 133.74% upper than Teladoc Health's previous annual EBITDA (Sep 23) of $40.39M.
Teladoc Health Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 16 | 8 | 5 | 10 | 11 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-57.07M | $-65.18M | $-69.23M | $-3.81B | $-73.48M | $-3.10B | $-6.67B | $-10.98M | $-84.34M | $-133.82M | $-199.65M | $-393.97M | $-35.88M |
| Avg Forecast | $30.64M | $-17.02M | $-34.05M | $-45.96M | $-32.57M | $-41.28M | $-43.89M | $-59.50M | $-25.37M | $-37.11M | $-40.54M | $-53.91M | $-38.50M | $-47.15M | $-58.66M | $-379.42B | $-37.33M | $-62.05M | $-69.19M | $-405.80B | $-20.39M | $-96.25M | $-104.02M | $-434.01B | $-96.73M | $-114.37M | $-89.96M | $-187.60M | $-44.23M | $-54.76M |
| High Forecast | $32.08M | $-16.08M | $-32.16M | $-43.42M | $-30.77M | $-39.00M | $-41.46M | $-56.21M | $-23.97M | $-35.06M | $-38.30M | $-31.45M | $4.28M | $-44.54M | $-55.42M | $-303.54B | $27.15M | $-45.28M | $-65.37M | $-324.64B | $-16.31M | $-96.25M | $-104.02M | $-347.21B | $-96.73M | $-114.37M | $-89.96M | $-150.08M | $-44.23M | $-54.76M |
| Low Forecast | $28.95M | $-17.82M | $-35.64M | $-48.12M | $-34.10M | $-43.21M | $-45.95M | $-62.29M | $-26.56M | $-38.85M | $-42.44M | $-67.39M | $-55.62M | $-49.36M | $-61.41M | $-455.31B | $-49.20M | $-77.14M | $-72.44M | $-486.96B | $-24.47M | $-96.25M | $-104.02M | $-520.81B | $-96.73M | $-114.37M | $-89.96M | $-225.12M | $-44.23M | $-54.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.94% | 0.00% | 186.85% | 0.76% | 29.82% | 0.02% | 0.11% | 0.74% | 1.49% | 1.06% | 8.91% | 0.66% |
Teladoc Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TDOC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Teladoc Health SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 16 | 8 | 5 | 10 | 11 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $301.87M | $358.13M | $345.43M | $322.57M | $346.10M | $333.37M | $296.85M | $290.92M | $276.70M | $278.29M | $259.40M | $531.68M | $135.53M |
| Avg Forecast | $477.35M | $465.88M | $456.28M | $446.30M | $399.52M | $394.24M | $392.32M | $391.70M | $386.06M | $382.59M | $382.03M | $383.13M | $386.59M | $382.88M | $393.79M | $386.60M | $406.92M | $402.50M | $393.80M | $375.67M | $540.02M | $369.36M | $355.92M | $344.96M | $331.91M | $313.39M | $303.67M | $243.75M | $229.86M | $171.17M |
| High Forecast | $494.58M | $482.70M | $472.74M | $462.40M | $413.94M | $408.47M | $406.48M | $405.84M | $399.99M | $396.39M | $395.82M | $395.37M | $392.47M | $383.06M | $393.88M | $386.60M | $409.54M | $409.18M | $408.01M | $389.23M | $648.03M | $369.36M | $355.92M | $344.96M | $331.91M | $313.39M | $303.67M | $292.50M | $229.86M | $171.17M |
| Low Forecast | $457.07M | $446.09M | $436.89M | $427.34M | $382.54M | $377.49M | $375.65M | $375.06M | $369.65M | $366.33M | $365.80M | $364.63M | $373.60M | $382.69M | $393.69M | $386.60M | $404.91M | $398.03M | $377.07M | $359.71M | $432.02M | $369.36M | $355.92M | $344.96M | $331.91M | $313.39M | $303.67M | $195.00M | $229.86M | $171.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.91% | 0.92% | 0.60% | 0.94% | 0.94% | 0.86% | 0.88% | 0.88% | 0.92% | 1.06% | 2.31% | 0.79% |
Teladoc Health's average Quarter SG&A projection for Dec 23 is $406.92M, based on 11 Wall Street analysts, with a range of $404.91M to $409.54M. The forecast indicates a 34.80% rise compared to TDOC last annual SG&A of $301.87M (Sep 23).
Teladoc Health EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 16 | 8 | 5 | 10 | 11 | 22 | 11 | 11 | 16 | 10 | 10 | 18 | 11 | 13 | 21 | 11 | 15 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.35 | $-0.40 | $-0.42 | $-23.49 | $-0.45 | $-19.22 | $-41.58 | $-0.07 | $-0.53 | $-0.86 | $-1.31 | $-3.07 | $-0.43 |
| Avg Forecast | $0.18 | $-0.10 | $-0.20 | $-0.27 | $-0.19 | $-0.24 | $-0.26 | $-0.35 | $-0.15 | $-0.22 | $-0.24 | $-0.32 | $-0.23 | $-0.28 | $-0.34 | $-0.46 | $-0.22 | $-0.36 | $-0.41 | $-0.48 | $-0.25 | $-0.57 | $-0.61 | $-0.60 | $-0.57 | $-0.67 | $-0.53 | $-0.54 | $-0.26 | $-0.32 |
| High Forecast | $0.19 | $-0.09 | $-0.19 | $-0.26 | $-0.18 | $-0.23 | $-0.24 | $-0.33 | $-0.14 | $-0.21 | $-0.23 | $-0.18 | $0.03 | $-0.26 | $-0.33 | $-0.43 | $0.16 | $-0.27 | $-0.38 | $-0.46 | $-0.23 | $-0.57 | $-0.61 | $-0.60 | $-0.57 | $-0.67 | $-0.53 | $-0.54 | $-0.26 | $-0.32 |
| Low Forecast | $0.17 | $-0.10 | $-0.21 | $-0.28 | $-0.20 | $-0.25 | $-0.27 | $-0.37 | $-0.16 | $-0.23 | $-0.25 | $-0.40 | $-0.33 | $-0.29 | $-0.36 | $-0.48 | $-0.29 | $-0.45 | $-0.43 | $-0.51 | $-0.26 | $-0.57 | $-0.61 | $-0.60 | $-0.57 | $-0.67 | $-0.53 | $-0.54 | $-0.26 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.98% | 0.87% | 95.51% | 0.80% | 31.46% | 69.43% | 0.12% | 0.79% | 1.63% | 2.42% | 11.82% | 1.34% |
According to undefined Wall Street analysts, Teladoc Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TDOC previous annual EPS of $NaN (undefined).
Teladoc Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TDOC | Teladoc Health | $8.87 | $50.87 | 473.51% | Hold |
| ACCD | Accolade | $3.15 | $14.81 | 370.16% | Buy |
| GDRX | GoodRx | $5.87 | $14.57 | 148.21% | Buy |
| PGNY | Progyny | $15.15 | $29.00 | 91.42% | Hold |
| TXG | 10x Genomics | $16.78 | $30.20 | 79.98% | Hold |
| SDGR | Schrödinger | $18.24 | $28.67 | 57.18% | Buy |
| VEEV | Veeva Systems | $212.53 | $229.71 | 8.08% | Buy |
| GEHC | GE HealthCare | $86.99 | $93.40 | 7.37% | Buy |
| DOCS | Doximity | $41.82 | $39.29 | -6.05% | Buy |
| TALK | Talkspace | $3.13 | $2.50 | -20.13% | Hold |
TDOC Forecast FAQ
Is Teladoc Health a good buy?
No, according to 21 Wall Street analysts, Teladoc Health (TDOC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 47.62% of TDOC's total ratings.
What is TDOC's price target?
Teladoc Health (TDOC) average price target is $50.87 with a range of $9 to $150, implying a 473.51% from its last price of $8.87. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Teladoc Health stock go up soon?
According to Wall Street analysts' prediction for TDOC stock, the company can go up by 473.51% (from the last price of $8.87 to the average price target of $50.87), up by 1591.09% based on the highest stock price target, and up by 1.47% based on the lowest stock price target.
Can Teladoc Health stock reach $13?
TDOC's average twelve months analyst stock price target of $50.87 supports the claim that Teladoc Health can reach $13 in the near future.
What is Teladoc Health's current price target trend?
2 Wall Street analysts forecast a $10 price target for Teladoc Health (TDOC) this month, up 12.74% from its last price of $8.87. Compared to the last 3 and 12 months, the average price target increased by 12.74% and increased by 48.14%, respectively.
What are Teladoc Health's analysts' financial forecasts?
Teladoc Health's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.6B (high $2.69B, low $2.49B), average EBITDA is $366.07M (high $379.28M, low $350.52M), average net income is $-177M (high $-167M, low $-186M), average SG&A $1.58B (high $1.63B, low $1.51B), and average EPS is $-1.041 (high $-0.984, low $-1.09). TDOC's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $3.04B (high $3.15B, low $2.91B), average EBITDA is $428.25M (high $443.71M, low $410.06M), average net income is $-66.39M (high $-59.592M, low $-72.634M), average SG&A $1.85B (high $1.91B, low $1.77B), and average EPS is $-0.39 (high $-0.35, low $-0.427).
Did the TDOC's actual financial results beat the analysts' financial forecasts?
Based on Teladoc Health's last annual report (Dec 2022), the company's revenue was $2.41B, beating the average analysts forecast of $2.4B by 0.38%. Apple's EBITDA was $13.47B, missing the average prediction of $-429B by -103.14%. The company's net income was $-13.66B, missing the average estimation of $-434B by -96.85%. Apple's SG&A was $1.3B, missing the average forecast of $1.61B by -19.23%. Lastly, the company's EPS was $-84.6, beating the average prediction of $-2.021 by 4085.59%. In terms of the last quarterly report (Sep 2023), Teladoc Health's revenue was $660.24M, missing the average analysts' forecast of $663.54M by -0.50%. The company's EBITDA was $40.39M, missing the average prediction of $93.39M by -56.75%. Teladoc Health's net income was $-57.073M, missing the average estimation of $-62.05M by -8.02%. The company's SG&A was $301.87M, missing the average forecast of $402.5M by -25.00%. Lastly, the company's EPS was $-0.35, missing the average prediction of $-0.365 by -3.98%